http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006528957-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
filingDate 2004-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2006-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2006528957-A
titleOfInvention Indole derivatives with improved antipsychotic efficacy
abstract [Chemical 1] The present invention relates to variables R 1 , R 2 , R 3 , R 4 , R 5 , p, a 1 = a 2 −a 3 = a 4 , Z 1 −Z 2 , X and Y defined in claim 1. A novel indole derivative of formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereoisomeric form thereof, an N-oxide form thereof or a quaternary ammonium thereof Regarding salt. The derivative exhibits binding affinity for dopamine receptors, in particular for dopamine D 2 , D 3 and D 4 receptors, has selective serotonin reuptake inhibition and 5-HT 1A agonists or moieties Acts as an agonist. The present invention relates to a pharmaceutical composition comprising a compound according to the invention, for the prevention and / or treatment of a series of psychotic and neurological disorders, in particular certain psychiatric disorders, in particular interpersonal phobia. And their use, and their method of manufacture.
priorityDate 2003-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID574140
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID15567
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6532
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID282365
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID135518
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164166570
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466036984
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID32247
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID135518
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID32247
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25553

Total number of triples: 39.